G-202-006: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

Trial Profile

G-202-006: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Mipsagargin (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Inspyr Therapeutics
  • Most Recent Events

    • 22 Feb 2017 Status changed from recruiting to completed.
    • 06 Sep 2016 According to a Inspyr media release, first patient has been treated in this trial. The company expects top-line results second half 2017.
    • 02 Jul 2016 Planned End Date changed from 1 Aug 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top